Doug Fisher

Doug joined InterWest’s healthcare team in 2009, focusing on biopharmaceutical, diagnostic, and medical device investments, and portfolio company support. In addition to Lycera, Doug is a board member of Gynesonics, Indi Molecular, and Obalon Therapeutics (OBLN). Doug is also actively involved in InterWest’s investments in Integrated Diagnostics, PMV Pharma, Potenza Therapeutics, Sera Prognostics (where he serves as the Chief Business Officer), Tizona Therapeutics, and Trieza Therapeutics.

Prior to joining InterWest, Doug was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix (Acquired by Biogen Idec). Prior to joining New Leaf, Doug was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area, consulting for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group.

Doug received an A.B. in economics with honors and distinction, and a B.S. in biology with distinction, from Stanford, where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton, where he graduated with honors as a Siebel Scholar and Palmer Scholar.